Press Releases July 27, 2026 04:05 PM

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Definitive Healthcare awards RSUs as inducement for new SVP and Head of AI & Data - Product

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
DH

Definitive Healthcare announced the granting of inducement awards comprising 1,063,830 time-based restricted stock units to their newly hired SVP and Head of AI & Data - Product, Srinivas Attipalli. The RSUs will vest over a period starting June 2027, contingent on continued employment. This move aligns with Nasdaq rules for inducement grants and supports the company’s strategic focus on data and AI within healthcare commercial intelligence.

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
DH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Definitive Healthcare hired Srinivas Attipalli as SVP and Head of AI & Data - Product and granted inducement RSUs to secure his employment.
  • 1,063,830 restricted stock units were awarded, vesting starting June 2027 in quarterly installments thereafter.
  • The awards comply with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants for newly hired executives.

FRAMINGHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Srinivas Attipalli of the Company, Definitive Healthcare’s new SVP and Head of AI & Data - Product, an inducement award consisting of 1,063,830 time-based restricted stock units (“RSUs”), effective July 24, 2026. These awards were individually negotiated and granted as an inducement material to Mr. Attipalli’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant.

Mr. Attipalli’s RSUs will vest as follows, subject to Mr. Attipalli’s continued employment through each such date: (i) 25% will vest on June 1, 2027; (ii) the remainder will vest in quarterly installments equal to 6.25% thereafter, until fully vested.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
[email protected]
646-277-1251

Media Contact:
Bethany Swackhamer
[email protected]


Risks

  • The inducement RSUs are contingent on Mr. Attipalli's continued employment potentially affecting future compensation expenses.
  • Market reaction may be muted as this is a common practice and does not indicate immediate financial performance improvements.
  • Execution risk exists related to translation of AI and data product strategies into commercial success impacting Definitive Healthcare and health tech sectors.

More from Press Releases

Blue Gold Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency Jul 27, 2026 Mueller Water Products Announces Dates for Third Quarter 2026 Earnings Release and Conference Call Jul 27, 2026 Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026 Jul 27, 2026 Millicom (Tigo) notice of second quarter 2026 results and video conference Jul 27, 2026 Celestica Announces Second Quarter 2026 Financial Results Jul 27, 2026